Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms
October 02, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
Results showed that younger age, non-visceral disease, prior tamoxifen and a longer total duration of AI use may be associated with higher baseline vaginal and/or vulvar symptomatologyFindings were...
Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
September 05, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting
June 29, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancerSecond poster shares survey results examining vaginal and sexual health in ER+/HER2-...
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
June 26, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
Sermonix used the Tempus TIME Trial® Network to enroll 45% of its ELAINE-2 patientsThe company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June ...
Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer
June 05, 2023 09:01 ET
|
Sermonix Pharmaceuticals Inc.
CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023
May 25, 2023 17:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Sermonix Pharmaceuticals Announces E-Poster Presentation on I-SPY 2 Study of Neoadjuvant Lasofoxifene at St. Gallen International Breast Cancer Conference 2023
March 15, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
VIENNA, Austria, March 15, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
March 09, 2023 08:00 ET
|
Sermonix Pharmaceuticals Inc.
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and...
Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
March 06, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and...
Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
February 13, 2023 09:15 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, and SAN FRANCISCO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix’s investigational...